Table 3:
Univariate Analyses for MCS with/without Treatment-Time and Covariates-Time Interaction Terms
| Variable | MCS Model with Treatment Effect | MCS Model without Treatment Effect | ||||||
|---|---|---|---|---|---|---|---|---|
| β | SE | 95%CI | P-Value | β | SE | 95%CI | P-Value | |
| HAART HAART-Naïve NPI-HAART Off-HAART PI-HAART |
−1.62 −0.01 −1.98 Ref. |
0.97 0.69 0.99 Ref. |
−3.53 – 0.29 −1.37 – 1.35 −3.92 – − 0.05 Ref. |
0.07$$
0.10 0.99 0.04 Ref. |
−0.50 0.50 −1.05 Ref. |
0.69 0.53 0.75 Ref. |
−1.87 – 0.87 −0.55 – 1.55 −2.52 – 0.42 Ref. |
0.06$$ 0.47 0.35 0.16 Ref. |
| Time (One-Yearly Increment) | −0.04 | 0.14 | −0.31 – 0.22 | 0.76 | 0.10 | 0.08 | −0.06 – 0.25 | 0.24 |
| HAART*Time HAART-Naïve*Time NPI-HAART*Time Off-HAART*Time PI-HARRT*Time |
0.55 0.09 0.50 Ref. |
0.35 0.18 0.34 Ref. |
-0.13 – 1.24 −0.26 – 0.45 −0.16 – 1.16 Ref. |
0.25$$
0.11 0.61 0.14 Ref |
||||
| Intercept for HAART | 48.24 | 0.53? | 47.19 – 49.28 | <.0001 | 47.73 | 0.48 | 46.79 – 48.67 | <.0001 |
| Race/Ethnicity Non-Hispanic African-American Others including Hispanics Non-Hispanic White |
2.71 1.21 Ref. |
0.60 0.87 Ref. |
1.54 – 3.88 −0.50 – 2.91 Ref. |
<.0001$$
<.0001 0.17 Ref. |
||||
| Time (One-Yearly Increment) | 0.11 | 0.08 | −0.05 – 0.27 | 0.17 | ||||
| Intercept for Race/Ethnicity | 46.59 | 0.45 | 45.71 – 47.47 | <.0001 | ||||
| Male | 0.69 | 1.32 | −1.89 – 3.27 | 0.60 | ||||
| Time (One-Yearly Increment) | 0.11 | 0.08 | −0.05 – 0.27 | 0.18 | ||||
| Intercept for Male | 47.16 | 1.30 | 44.61 – 49.71 | <.0001 | ||||
| Rank Civilian/Not Active Duty Enlisted Warrant Officer/Officer |
−2.44 −1.39 Ref. |
1.31 1.31 Ref. |
−5.01 – 0.12 −3.97 – 1.19 Ref. |
0.09$$ 0.03 0.20 Ref. |
−1.58 −0.50 Ref. |
1.08 1.09 Ref. |
−3.69 – 0.53 −2.63 – 1.64 Ref. |
0.08$$
0.14 0.65 Ref. |
| Time (One-Yearly Increment) | −0.22 | 0.29 | −0.79 – 0.34 | 0.44 | 0.12 | 0.08 | −0.04 – 0.28 | 0.14 |
| Rank*Time Civilian/Not Active Duty*Time Enlisted*Time Warrant Officer/Officer |
0.36 0.38 Ref. |
0.31 0.31 Ref. |
−0.24 – 0.97 −0.24 – 0.99 Ref. |
0.46$$
0.07 0.07 Ref. |
||||
| Intercept for Rank | 49.58 | 1.22 | 47.19 – 51.98 | <.0001 | 48.77 | 1.03 | 46.75 – 50.79 | <.0001 |
| Married | −0.26 | 0.63 | −1.49 – 0.97 | 0.68 | 0.50 | 0.47 | −0.42 – 1.41 | 0.29 |
| Time (One-Yearly Increment) | −0.01 | 0.10 | −0.19 – 0.20 | 0.95 | 0.11 | 0.08 | −0.05 – 0.27 | 0.18 |
| Married*Time | 0.32 | 0.18 | −0.03 – 0.67 | 0.07 | ||||
| Intercept for Married | 47.90 | 0.40 | 47.12 – 48.69 | <.0001 | 47.65 | 0.37 | 46.92 – 48.39 | <.0001 |
| Medical Comorbidity | −0.76 | 0.81 | −2.35 – 0.83 | 0.35 | −0.60 | 0.54 | −1.65 – 0.45 | 0.26 |
| Time (One-Yearly Increment) | 0.11 | 0.09 | −0.07 – 0.29 | 0.22 | 0.12 | 0.08 | −0.04 – 0.28 | 0.13 |
| Medical Comorbidity*Time | 0.05 | 0.21 | −0.36 – 0.46 | 0.80 | ||||
| Intercept for Medical Comorbidity | 47.92 | 0.36 | 47.21 – 48.64 | <.0001 | 47.89 | 0.35 | 47.21 – 48.58 | <.0001 |
| Mental Comorbidity | −4.90 | 0.67 | −6.21 – −3.58 | <.0001 | −4.75 | 0.49 | −5.70 – −3.80 | <.0001 |
| Time (One-Yearly Increment) | 0.16 | 0.10 | −0.03 – 0.35 | 0.10 | 0.17 | 0.08 | 0.02 – 0.33 | 0.03 |
| Mental Comorbidity*Time | 0.06 | 0.18 | −0.30 – 0.41 | 0.75 | ||||
| Intercept for Mental Comorbidity | 49.02 | 0.37 | 48.29 – 49.75 | <.0001 | 48.97 | 0.35 | 48.29 – 49.66 | <.0001 |
| Baseline Age (5-yearly Increments) | 0.24 | 0.15 | −0.06 – 0.54 | 0.11 | ||||
| Time (One-Yearly Increment) | 0.11 | 0.08 | −0.05 – 0.27 | 0.18 | ||||
| Intercept for Baseline Age | 45.78 | 1.34 | 43.16 – 48.40 | <.0001 | ||||
| Time since HIV Diagnosis (5yearly Increments) | −0.24 | 0.27 | −0.77 – 0.29 | 0.38 | −0.22 | 0.23 | −0.66 – 0.22 | 0.33 |
| Time (One-Yearly Increment) | 0.13 | 0.18 | −0.23 – 0.49 | 0.48 | 0.15 | 0.09 | −0.03 – 0.33 | 0.10 |
| Time since HIV Diagnosis*Time | 0.01 | 0.06 | −0.12 – 0.13 | 0.91 | ||||
| Intercept for Time since HIV Diagnosis | 48.28 | 0.65 | 46.99 – 49.56 | <.0001 | 48.23 | 0.55 | 47.16 – 49.31 | <.0001 |
| pVL >50copies/mL | −1.65 | 0.56 | −2.76 – −0.54 | 0.004 | −0.87 | 0.33 | −1.52 – −0.22 | 0.009 |
| Time (One-Yearly Increment) | −0.03 | 0.10 | −0.23 – 0.16 | 0.73 | 0.06 | 0.08 | −0.10 – 0.22 | 0.46 |
| pVL*Time | 0.32 | 0.19 | −0.05 – 0.70 | 0.08 | ||||
| Intercept for pVL | 48.49 | 0.41 | 47.69 – 49.29 | <.0001 | 48.23 | 0.38 | 47.49 – 48.97 | <.0001 |
| CD4 Category CD4 Count <200 CD4 Count 2–499 CD4 Count >499 |
−2.93 −1.17 Ref. |
1.36 0.58 Ref. |
−5.61 – 0.26 −2.31 – −0.03 Ref. |
0.03$$
0.03 0.04 Ref. |
−2.77 −0.54 Ref. |
0.87 0.34 Ref. |
−4.48 – −1.06 −1.21 – 0.13 Ref. |
0.005$$
0.002 0.11 Ref. |
| Time (One-Yearly Increment) | −0.01 | 0.10 | −0.21 – 0.20 | 0.96 | 0.08 | 0.08 | −0.08 – 0.24 | 0.35 |
| CD4 Category*Time CD4 Count <200*Time CD4 Count 2–499*Time CD4 Count >499*Time |
0.07 0.25 Ref. |
0.45 0.18 Ref. |
−0.81 – 0.96 −0.11 – 0.61 |
0.41$$
0.87 0.18 Ref. |
||||
| Intercept for CD4 category | 48.46 | 0.42 | 47.63 – 49.28 | <.0001 | 48.22 | 0.38 | 47.48 – 48.97 | <.0001 |
| AIDS Defining Illness | −1.57 | 1.10 | −3.72 – 0.58 | 0.15 | −0.82 | 0.85 | −2.49 – 0.85 | 0.34 |
| Time (One-Yearly Increment) | 0.08 | 0.08 | −0.08 – 0.25 | 0.34 | 0.11 | 0.08 | −0.05 – 0.27 | 0.17 |
| AIDS Defining Illness*Time | 0.30 | 0.28 | −0.17 – 0.92 | 0.28 | ||||
| Intercept for AIDS Defining Illness | 47.97 | 0.36 | 47.27 – 48.67 | <.0001 | 47.90 | 0.35 | 47.21 – 48.58 | <.0001 |
| Medical Comorbidity Category Diabetes CV disorder/MI Cancers Other Chronic Medical Condition No Med Comorbidity Category |
−1.42 −0.68 −0.29 −0.27 Ref. |
1.19 2.30 1.24 2.12 Ref. |
−3.75 – 0.90 −5.18 – 3.83 −2.73 – 2.14 −4.44 – 3.89 Ref. |
0.83$$
0.23 0.77 0.81 0.90 Ref. |
−0.63 −1.53 −0.94 1.11 Ref. |
0.83 1.12 0.84 1.17 Ref. |
−2.26 – 0.99 −3.72 – 0.66 −2.58 – 0.70 −1.18 – 3.41 Ref. |
0.35$$
0.45 0.17 0.26 0.34 Ref. |
| Time (One-Yearly Increment) | 0.11 | 0.09 | −0.07 – 0.29 | 0.22 | 0.12 | 0.08 | −0.04 – 0.28 | 0.14 |
| Medical Comorbidity Category*Time Diabetes*Time CV disorder/MI*Time Cancers*Time Other Chronic Medical Condition*Time No Medical Comorbidity*Time |
0.28 −0.25 −0.24 0.43 Ref. |
0.31 0.59 0.33 0.55 Ref. |
−0.32 – 0.89 −1.41 – 0.91 −0.89 – 0.41 −0.66 – 1.51 Ref. |
0.70$$
0.36 0.67 0.47 0.44 Ref. |
||||
| Intercept for Med Comorbidity Category | 47.93 | 0.36 | 47.21 – 48.64 | <.0001 | 47.90 | 0.35 | 47.21 – 48.59 | <.0001 |
| Mental Comorbidity Category MDD Anxiety/Bipolar Disorders Alcohol Abuse Other Psychiatric Disorders No Psychiatric Disorder |
−5.56 −4.74 −2.59 −2.27 Ref. |
0.76 1.41 1.59 2.07 Ref. |
−7.06 – 4.06 −7.51 – − 1.96 −5.70 – 0.52 −6.32 – 1.78 Ref. |
<.0001$$
<.0001 0.0008 0.10 0.27 Ref. |
−5.05 −5.44 −3.48 −3.09 Ref. |
0.55 0.84 1.05 1.05 Ref. |
−6.13 – −3.96 −7.08 – −3.79 −5.54 – −1.42 −5.16 – −1.03 Ref. |
<.0001$$
<.0001 <.0001 0.001 0.003 Ref. |
| Time (One-Yearly Increment) | 0.16 | 0.10 | −0.03 – 0.35 | 0.10 | 0.17 | 0.08 | 0.01 – 0.32 | 0.04 |
| Mental Comorbidity Category*Time MDD*Time Anxiety/Bipolar Disorders Alcohol Abuse*Time Other Psychiatric Disorders*Time No Psychiatric Disorder*Time |
0.21 −0.26 −0.34 −0.24 Ref. |
0.22 0.40 0.45 0.57 Ref. |
−0.22 – 0.64 −1.05 – 0.53 −1.22 – 0.54 −1.36 – 0.88 Ref. |
0.68$$
0.33 0.52 0.45 0.67 Ref. |
||||
| Intercept for Mental Comorbidity Category | 49.02 | 0.37 | 48.29 – 49.75 | <.0001 | 49.00 | 0.35 | 48.32 – 49.68 | <.0001 |
$$
p-value of F-statistics of type 3 tests of the fixed effects
PCS: physical component summary scores; MCS: mental component summary scores; HAART: highly active antiretroviral therapy; PI-HAART: protease inhibitor-based HAART; NPI-HAART: non-protease inhibitor-based HAART; HAART-naïve: never received HAART; Off-HAART: received HAART in the past but not currently on HAART; β: beta; SE: standard error; 95%CI: 95% confidence interval; pVL: plasma viral load; Med: Medical; MDD Major Depressive Disorder; CV: Cardiovascular; MI: Myocardial Infarction